Diabetes Risk Begins In Utero  by Woo, Melissa & Patti, Mary-Elizabeth
when the life-span defect of SIR2 deletion
is suppressed by deletion of a second
gene, FOB1, mother cells respond ro-
bustly to dietary restriction and live
substantially longer than wild-type cells
(Kaeberlein et al., 2004).
Whatmakes the study by Li et al. partic-
ularly interesting is the observation that
SirT1 inhibition causes some phenotypes
more consistent with a slower rate of
aging. For example, they show that SirT1
inhibition leads to increased IRS-2acetyla-
tion, decreased IGF-1 signaling, and de-
creased Ras/ERK signaling. Decreased
Ras signaling increases life span in yeast,
and reduced insulin/IGF-1-like signaling
is associated with increased life span in
worms, flies, and mice. Supporting the
idea that inhibition of SirT1 may slow as-
pects of aging in mice, Li et al. proceed
to show enhanced resistance to oxidative
stress in neuronal cells after SirT1 knock-
down and reduced oxidation of proteins
and lipids in brains of SirT1 knockout ani-
mals. Taken together, these datamay indi-
cate that inhibition of SirT1 can be neuro-
protective in aging animals and that some
features of aging are slowed rather than
accelerated in SirT1 knockout animals.
So what’s the ‘‘take-home message’’
from all this? Is more SirT1 good, or is
less SirT1 good? The answer, as is often
thecase inbiology, is that there’s nosimple
answer.ActivatingSirT1 isprobablyagood
thing in some cells under some conditions
and is probably a bad thing in other cells
under other conditions. SirT1 activators
may be good for diabetes but may cause
cancer due to p53 inhibition, SirT1 inhibi-
tors may protect against cancer but cause
metabolic disease, and there is evidence
supporting the idea that both activators
and inhibitors of SirT1 can confer protec-
tion against neurodegeneration in different
contexts. The one thing that seems clear is
that sirtuin activators are unlikely to be
a ‘‘magic bullet’’ for aging. A more realistic
hope is that, as we continue to unravel the
complexitiesof sirtuinbiology, targetedac-
tivation or inhibition of SirT1—and perhaps
other sirtuins as well—will prove therapeu-
tically useful toward a subset of age-asso-
ciated diseases. Such an achievement
would be a huge step forward in the transi-
tion of aging-related science from the labo-
ratory to the clinic, and we eagerly await
the next chapter in the unfolding saga that
is sirtuin biology.
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Both intrauterine and postnatal environments contribute to diabetes risk. A recent paper highlights epige-
netic mechanisms underlying b cell dysfunction associated with intrauterine growth retardation, including
repressive histone modification and DNA methylation during postnatal life. Thus, intrauterine stress can
initiate a disturbing epigenetic cascade of progressive transcriptional repression linked to b cell failure.The prevalence of childhood obesity
and type 2 diabetes (DM) has increased
dramatically in the past 50 years. While
overnutrition and a sedentary lifestyle
clearly contribute to these findings, the in-
trauterine and early postnatal environ-
ment are also key contributors to obesityand DM risk. A recent paper (Park et al.,
2008) highlights epigenetic mechanisms
linking intrauterine growth retardation to
b cell dysfunction and diabetes risk.
The association between low birth
weight and adult disease was first re-
ported by David Barker (Barker et al.,Cell Me1989). Barker accessed the records of
15,000 men and women born before
1930 whose medical history was meticu-
lously documented by nurses in Hertford-
shire, England. Using this information,
he made a landmark observation: Birth
weight is inversely correlated with the risktabolism 8, July 2008 ª2008 Elsevier Inc. 5
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Previewsof cardiovascular disease in adulthood.
This observation spurred subsequent epi-
demiological studies in multiple countries
that revealed a strong association be-
tween fetal growth retardation, low birth
weight, and increased risk of DM and car-
diovascular disease (Barker et al., 1993).
In addition to low birth weight, rapid
postnatal weight gain is also associated
with increased susceptibility to obesity
and DM. Thus, individuals who are both
small at birth and have accelerated early
postnatal (‘‘catchup’’) growth are at very
high risk for central obesity and DM.
Rapid weight gain later in childhood and
early timing of adiposity rebound (mini-
mum BMI during early childhood) also
predict adult disease risk (Barker et al.,
2005). Experimentally, prevention of post-
natal catchup growth normalizes both
glucose intolerance and obesity (Jime-
nez-Chillaron et al., 2006).
Together, such data have led to the for-
mulation of the developmental origins of
adult disease hypothesis, which proposes
that nutritional or environmental stimuli,
acting during critical windows in develop-
ment, can have a lasting impact on cellu-
lar structure and function and on patterns
of adult disease (Barker et al., 1989).
Thus, early life stressors such as maternal
undernutrition, maternal obesity, cortico-
steroid therapy, uteroplacental insuffi-
ciency, or hypoxia, particularly when fol-
lowed by accelerated postnatal growth
and/or positive caloric balance, may
‘‘program’’ metabolic adaptations that
favor survival initially, but are ultimately
detrimental to adult health. Interestingly,
some phenotypes associated with low
birth weight can also be transmitted to
a second generation, initiating a vicious
cycle of DM risk (Drake andWalker, 2004).
The molecular mechanisms mediating
risk associated with a suboptimal intra-
uterine and early postnatal environment
have not been fully elucidated. However,
several lines of evidence indicate that epi-
genetic modification may be a key unify-
ing mechanism. First, disruption of physi-
ologic responses and functional capacity
is observed in multiple tissues of LBW
animals and humans, including muscle,
adipose, pancreatic b cells, liver, and
CNS (Jensen et al., 2007; Jimenez-Chill-
aron et al., 2005; Fu et al., 2004). These
tissue effects may be related to altered
gene expression, in turn potentially medi-
ated by histone modification and DNA6 Cell Metabolism 8, July 2008 ª2008 Elseviemethylation effects on chromatin struc-
ture. DNA methylation, although typically
relatively stable during adult life, can be al-
tered by the early-life nutrient/metabolic
environment (Waterland and Jirtle, 2003).
Histone modification is a more dynamic
regulatoryprocess,but canalsobealtered
by the intrauterine and postnatalmilieu (Fu
et al., 2004). Finally, both epigenetic mod-
ification and phenotypes linked to early
nutrition canbe transmitted to subsequent
generations and may contribute to ‘‘inter-
generational programming’’ of obesity
and DM risk (Drake and Walker, 2004).
The recent publication of Park et al.
(2008) further expands our knowledge of
the epigenetic patterns associated with
adult metabolic phenotypes resulting
from intrauterine stress. Simmonsandcol-
leagues have previously developed a rat
model of intrauterine growth retardation
(IUGR) produced by uterine artery ligation;
IUGR offspring develop impaired b cell
mass, insulin secretory dysfunction, and
DM with aging. A consistent finding
in this model is progressive reduction in
expression of PDX1, a key transcription
factor regulating pancreatic development
and function (Stoffers et al., 2003); during
fetal life, expression of PDX1 is reduced
by 50% in IUGR fetuses and by 80% in
adult rats with a history of IUGR. Notably,
these changes precede the onset of
b cell dysfunction, suggesting a primary
pathogenic role.
The PDX promoter is a target for epige-
netic modification, as it contains a con-
served CpG island (potential site of
altered DNA methylation) and is associ-
ated with high levels of histone acetyla-
tion. Park and colleagues asked whether
alterations in histone modification may
mediate reduced activity of the PDX
promoter. Interestingly, binding of both
acetylated histone H3/H4 and the tran-
scription factor USF1 was abolished in
IUGR fetuses. By 2 weeks of age, these
changes were accompanied by reduced
binding of the activating H3K4me3,
increased binding of the repressive
H3K9me2, and increased binding of
HDAC1 and mSin3A. These patterns in-
creased by 6 months of age, in parallel
with progressive loss of b cell function
in IUGR rats. Park and colleagues also
evaluated PDX1 promoter methylation
patterns using pyrosequencing of bisul-
fite-treated DNA. While there was 50%
methylation at multiple CpGs in IUGRr Inc.adults, in association with binding of
DNMT1 and 3a methyltransferases, no
methylation was detected in IUGR neo-
nates—indicating that methylation was
unlikely to explain PDX1 repression early
in life. Furthermore, DNA methyltransfer-
ase inhibition did not normalize PDX ex-
pression ex vivo, while patterns of histone
modification, USF binding to the PDX pro-
moter, and PDX expression were largely
normalized by HDAC inhibition.
Similar epigenetic patterns,with repres-
sive histone modifications without altered
DNAmethylation, have also been recently
associatedwith reducedexpression of the
GLUT4 glucose transporter in skeletal
muscle in rats with both intrauterine and
early postnatal caloric restriction (Ray-
chaudhuri et al., 2008). Together, these
data indicate that progressive silencing
of gene expression is largely linked to ab-
normal patterns of histone modification,
which can be observed within days
following the onset of intrauterine stress.
More importantly, these early epigenetic
changes initiate a disturbing pattern of
progressive transcriptional repression—
even in the absence of further experimen-
tal insults during postnatal life.
Together, these elegant studies provide
molecular evidence to support epigenetic
mechanisms linking the fetal environment
to progressive transcriptional dysregu-
lation and adult disease risk (Figure 1).
Many questions remain unanswered.
Which components of the intrauterine
metabolic environment initiate the devel-
opmental cascade of epigenetic modifi-
cation? Which mechanisms contribute to
progressive methylation with aging? Are
similar patterns observed for additional
key regulatory genes, in other models of
IUGR, in other tissues, or in humans?
These data on the surface may initially
provoke pessimism—that diabetes risk is
‘‘programmed’’ during prenatal life and
therefore less modifiable. However, ani-
mal studies indicate that there are critical
periods of developmental plasticity during
which nutritional andpharmacologic inter-
ventions can reverse abnormal metabolic
function and reduce the risk of adult
disease (Jimenez-Chillaron et al., 2006;
Stoffers et al., 2003). Thus, optimism
should arise from the implication that there
may be a window for potential postnatal
therapeutic interventions, particularly for
LBW children, via prevention of acceler-
ated postnatal growth and obesity onset.
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PreviewsIn the obesogenic environment of the
twenty-first century, we need to focus fur-
ther scientific attention to design and im-
plement novel nutritional and pharmaco-
logic strategies aimed at our youngest
at-risk population in order to interrupt the
vicious cycle of obesity and diabetes risk.The Double Life of
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Biol. 23, 5293–5300.Figure 1. Diabetes Risk Can Begin during Prenatal Life
Intrauterine stressors, including maternal undernutrition or placental dysfunction (leading to impaired
blood flow, nutrient transport, or hypoxia) can initiate abnormal patterns of development and histonemod-
ification. Additional postnatal environmental factors, including accelerated postnatal growth, obesity, in-
activity, and aging can further contribute to DM risk, potentially via further histone modifications and DNA
methylation in critical tissues.k, NY 10027, USA
s in this issue (Kubota et al., 2008;
mpt a critical reappraisal of the
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ing the signal engendered by receptor
autophosphorylation, and (3) engaging a
panoply of substrates that account for
thediverse actions of insulin (White, 2003).
Phenotypic differences between differ-
ent Irs knockout mice ushered in the idea
that Irs play distinct roles in different
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